246 related articles for article (PubMed ID: 34865516)
1. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
2. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
Liu S; Graves N; Tan AC
Lung Cancer; 2024 May; 191():107794. PubMed ID: 38636314
[TBL] [Abstract][Full Text] [Related]
5. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
6. Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
Gray JE; Han JY; Telaranta-Keerie A; Huang X; Kohlmann A; Hodge R; Rukazenkov Y; Chmielecki J; Espenschied CR; Lefterova M; Wu YL; Ramalingam SS; Barrett JC; Odegaard JI
J Mol Diagn; 2024 Jan; 26(1):73-84. PubMed ID: 37981090
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
[TBL] [Abstract][Full Text] [Related]
9. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
10. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.
Matsuda H; Ogawa T; Sadatsuki Y; Tsujino T; Wada S; Kim SW; Hatanaka Y
Respir Investig; 2023 Jan; 61(1):61-73. PubMed ID: 36460584
[TBL] [Abstract][Full Text] [Related]
12. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
14. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands.
Wolff HB; Steeghs EMP; Mfumbilwa ZA; Groen HJM; Adang EM; Willems SM; Grünberg K; Schuuring E; Ligtenberg MJL; Tops BBJ; Coupé VMH
JCO Precis Oncol; 2022 Jul; 6():e2200201. PubMed ID: 35834758
[TBL] [Abstract][Full Text] [Related]
16. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
18. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas.
Lin LH; Allison DHR; Feng Y; Jour G; Park K; Zhou F; Moreira AL; Shen G; Feng X; Sabari J; Velcheti V; Snuderl M; Cotzia P
Mod Pathol; 2021 Dec; 34(12):2168-2174. PubMed ID: 34362997
[TBL] [Abstract][Full Text] [Related]
19. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
